source
- EyePoint's Phase 3 trial fails, prompting 53% staff cuts; Lilly signs China drug delivery partnershipEyePoint, a Watertown, Massachusetts biotech, reported that its experimental therapy did not meet primary endpoints in a Phase 3 study, marking a setback for the company. Following the trial failu…
- HHS moves to let compounding pharmacies make select peptides as China tightens biotech exports but permits foreign licensingThe HHS announced a policy that would allow compounding pharmacies to produce certain peptide drugs, expanding access and potentially lowering costs. The move is part of the Trump administration's…